Wstęp
Ta strona zawiera kompleksową analizę znanej historii wykorzystywania informacji poufnych w firmie Versant Vantage I, L.P.. Insiderzy to członkowie kadry kierowniczej, dyrektorzy lub znaczący inwestorzy w spółce. Dokonywanie transakcji w ich firmach w oparciu o określone, niepubliczne informacje jest nielegalne. Nie oznacza to, że dokonywanie jakichkolwiek transakcji we własnych firmach jest nielegalne. Muszą jednak zgłaszać wszystkie transakcje do SEC za pośrednictwem formularza 4. Pomimo tych ograniczeń badania akademickie sugerują, że insiderzy – ogólnie rzecz biorąc – mają tendencję do osiągania lepszych wyników na rynku w swoich własnych firmach.
Średnia rentowność handlu
Średnia rentowność handlu to średni zwrot ze wszystkich zakupów na otwartym rynku dokonanych przez osobę mającą dostęp do informacji poufnych w ciągu ostatnich trzech lat. Aby to obliczyć, badamy każdy nieplanowany zakup na otwartym rynku dokonany przez insidera, z wyłączeniem wszystkich transakcji oznaczonych jako część planu handlowego 10b5-1. Następnie obliczamy średnią wydajność tych transakcji w ciągu 3, 6 i 12 miesięcy, uśredniając każdy z tych okresów, aby wygenerować ostateczny wskaźnik wydajności dla każdej transakcji. Na koniec uśredniamy wszystkie wskaźniki wydajności, aby obliczyć wskaźnik wydajności dla insidera. Na tej liście znajdują się wyłącznie insiderzy, którzy dokonali co najmniej trzech transakcji w ciągu ostatnich dwóch lat.
Jeśli rentowność handlu insiderów jest oznaczona notką„nie dotyczy”, oznacza to, że insider albo nie dokonał żadnych zakupów na otwartym rynku w ciągu ostatnich trzech lat, albo transakcje, których dokonał, są zbyt nowe, aby obliczyć wiarygodny wskaźnik wydajności.
Częstotliwość aktualizacji: codziennie
Spółki posiadające zgłoszone stanowiska osób mających dostęp do poufnych informacji
Z dokumentów SEC wynika, że Versant Vantage I, L.P. zgłosił udziały lub transakcje w następujących spółkach:
| Papier wartościowy | Nazwa | Najnowsze raporty dotyczące udziałów |
|---|---|---|
| US:LVTX / LAVA Therapeutics N.V. | 10% Owner | 0 |
| US:GLUE / Monte Rosa Therapeutics, Inc. | 10% Owner | 1 573 453 |
| US:BDTX / Black Diamond Therapeutics, Inc. | 10% Owner | 3 726 341 |
| 10% Owner | 148 312 | |
| US:OYST / Oyster Point Pharma Inc | 10% Owner | 0 |
| US:RPTX / Repare Therapeutics Inc. | 10% Owner | 0 |
| US:ALGS / Aligos Therapeutics, Inc. | 10% Owner | 0 |
| 10% Owner | 0 | |
| US:APRE / Aprea Therapeutics, Inc. | 10% Owner | 0 |
| US:PASG / Passage Bio, Inc. | 10% Owner | 0 |
Jak interpretować wykresy
Poniższe wykresy przedstawiają notowania akcji papierów wartościowych po każdej niezaplanowanej transakcji na otwartym rynku dokonanej przez Versant Vantage I, L.P.. Nieplanowane transakcje to transakcje, które nie zostały dokonane w ramach planu handlowego 10b5-1. Notowania akcji przedstawiono na wykresie jako skumulowaną procentową zmianę ceny akcji. Na przykład, jeśli 1 stycznia 2019 r. dokonano transakcji poufnej, wykres pokaże dzienną procentową zmianę papieru wartościowego do dnia dzisiejszego. Jeżeli cena akcji wzrosłaby w tym czasie z 10 do 15 dolarów, skumulowana procentowa zmiana ceny akcji wyniosłaby 50%. Zmiana ceny z 10$ na 20$ będzie wynosić 100%, a zmiana ceny z 10$ na 5$ będzie wynosić -50%.
Ostatecznie staramy się określić, jak blisko transakcje insiderów korelują z nadmiernymi zwrotami (dodatnimi lub ujemnymi) z ceny akcji, aby sprawdzić, czy insider dostosowuje swoje transakcje w taki sposób, aby czerpać korzyści z informacji poufnych. Rozważmy sytuację, w której zrobił to ktoś z wewnątrz. W tej sytuacji oczekiwalibyśmy albo (a) dodatnich zwrotów po zakupach, albo (b) ujemnych zwrotów po sprzedaży. W przypadku (a) wykres ZAKUPU pokazywałby serię krzywych nachylonych w górę, wskazujących dodatnie zwroty po każdej transakcji zakupu. W przypadku (b) wykres SPRZEDAŻ pokazywałby serię krzywych o nachyleniu w dół, wskazujących ujemne zwroty po każdej transakcji sprzedaży.
Samo to jednak nie wystarczy, aby wyciągnąć wnioski. Gdyby np. cena akcji spółki przez wiele lat rosła niecyklicznie, to spodziewalibyśmy się, że wszystkie wykresy po zakupie będą wykazywały tendencję wzrostową. Podobnie niecykliczne spadki na przestrzeni wielu lat spowodowałyby spadek linii na wykresie po transakcjach. Żaden z tych wykresów nie sugeruje wykorzystywania informacji poufnych.
Najsilniejszym wskaźnikiem byłaby sytuacja, gdy cena akcji miała charakter wyjątkowo cykliczny, a na wykresie KUPNO występowały zarówno pozytywne sygnały na wykresie KUPNA, jak i negatywne na wykresie SPRZEDAŻY. Sytuacja ta wysoce sugerowałaby osobę mającą dostęp do informacji poufnych, która wykorzystywała transakcje w celu uzyskania korzyści finansowej.
Zakupy insidera ALGS / Aligos Therapeutics, Inc. – krótkoterminowa analiza zysków
W tej części analizujemy rentowność każdego nieplanowanego zakupu od poufnych informacji na otwartym rynku dokonanego w ALGS / Aligos Therapeutics, Inc.. Analiza ta pomaga zrozumieć, czy insider konsekwentnie generuje nietypowe zyski i czy warto ją śledzić. Analiza ta obejmuje okres jednego roku po każdej transakcji, a wyniki mają charakter teoretyczny .
Poniższa tabela przedstawia najnowsze zakupy na otwartym rynku, które nie były częścią planu handlu automatycznego.
| Data transakcji | Ticker | Insider | Zgłoszone Akcje |
Zgłoszona Cena |
Skorygowane Akcje |
Skorygowana Cena |
Podstawa kalkulacji kosztów | Dni do maks |
Cena maks |
Maks Zysk ($) |
Maksymalny zwrot (%) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2020-10-20 | ALGS | Versant Venture Capital VI, L.P. | 200 000 | 15,0000 | 8 000 | 375,0000 | 3 000 000 | 92 | 34.94 | -2 720 480 | -90,68 |
Cena skorygowana to cena skorygowana o podział. Akcje skorygowane to akcje skorygowane o podział.
Sprzedaż insidera ALGS / Aligos Therapeutics, Inc. — analiza strat krótkoterminowych
W tej sekcji analizujemy możliwość uniknięcia krótkoterminowych strat w wyniku każdej nieplanowanej sprzedaży poufnych informacji na otwartym rynku dokonanej w ALGS / Aligos Therapeutics, Inc.. Konsekwentny wzorzec unikania strat może sugerować, że przyszłe transakcje sprzedaży mogą przewidywać spadki cen. Analiza ta obejmuje okres jednego roku po każdej transakcji, a wyniki mają charakter teoretyczny .
Poniższa tabela przedstawia najnowsze sprzedaże na otwartym rynku, które nie były częścią planu handlu automatycznego.
| Data transakcji | Ticker | Insider | Zgłoszone Akcje |
Zgłoszona Cena |
Skorygowane Akcje |
Skorygowana Cena |
Podstawa kalkulacji kosztów | Dni do min |
Cena min |
Uniknięta maksymalna strata ($) |
Uniknięta Maksymalna strata (%) |
|---|---|---|---|---|---|---|---|
| Nie znane są żadne nieplanowane transakcje na otwarttm rynku dla tej kombinacji insidera i papieru wartościowego |
Cena skorygowana to cena skorygowana o podział. Akcje skorygowane to akcje skorygowane o podział.
Zakupy insidera APRE / Aprea Therapeutics, Inc. – krótkoterminowa analiza zysków
W tej części analizujemy rentowność każdego nieplanowanego zakupu od poufnych informacji na otwartym rynku dokonanego w ALGS / Aligos Therapeutics, Inc.. Analiza ta pomaga zrozumieć, czy insider konsekwentnie generuje nietypowe zyski i czy warto ją śledzić. Analiza ta obejmuje okres jednego roku po każdej transakcji, a wyniki mają charakter teoretyczny .
Poniższa tabela przedstawia najnowsze zakupy na otwartym rynku, które nie były częścią planu handlu automatycznego.
| Data transakcji | Ticker | Insider | Zgłoszone Akcje |
Zgłoszona Cena |
Skorygowane Akcje |
Skorygowana Cena |
Podstawa kalkulacji kosztów | Dni do maks |
Cena maks |
Maks Zysk ($) |
Maksymalny zwrot (%) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2019-10-07 | APRE | Versant Vantage I, L.P. | 333 333 | 15,0000 | 16 667 | 300,0000 | 4 999 995 | 81 | 990.6 | 11 509 345 | 230,19 |
Cena skorygowana to cena skorygowana o podział. Akcje skorygowane to akcje skorygowane o podział.
Sprzedaż insidera APRE / Aprea Therapeutics, Inc. — analiza strat krótkoterminowych
W tej sekcji analizujemy możliwość uniknięcia krótkoterminowych strat w wyniku każdej nieplanowanej sprzedaży poufnych informacji na otwartym rynku dokonanej w ALGS / Aligos Therapeutics, Inc.. Konsekwentny wzorzec unikania strat może sugerować, że przyszłe transakcje sprzedaży mogą przewidywać spadki cen. Analiza ta obejmuje okres jednego roku po każdej transakcji, a wyniki mają charakter teoretyczny .
Poniższa tabela przedstawia najnowsze sprzedaże na otwartym rynku, które nie były częścią planu handlu automatycznego.
| Data transakcji | Ticker | Insider | Zgłoszone Akcje |
Zgłoszona Cena |
Skorygowane Akcje |
Skorygowana Cena |
Podstawa kalkulacji kosztów | Dni do min |
Cena min |
Uniknięta maksymalna strata ($) |
Uniknięta Maksymalna strata (%) |
|---|---|---|---|---|---|---|---|
| Nie znane są żadne nieplanowane transakcje na otwarttm rynku dla tej kombinacji insidera i papieru wartościowego |
Cena skorygowana to cena skorygowana o podział. Akcje skorygowane to akcje skorygowane o podział.
Zakupy insidera BDTX / Black Diamond Therapeutics, Inc. – krótkoterminowa analiza zysków
W tej części analizujemy rentowność każdego nieplanowanego zakupu od poufnych informacji na otwartym rynku dokonanego w ALGS / Aligos Therapeutics, Inc.. Analiza ta pomaga zrozumieć, czy insider konsekwentnie generuje nietypowe zyski i czy warto ją śledzić. Analiza ta obejmuje okres jednego roku po każdej transakcji, a wyniki mają charakter teoretyczny .
Poniższa tabela przedstawia najnowsze zakupy na otwartym rynku, które nie były częścią planu handlu automatycznego.
Cena skorygowana to cena skorygowana o podział. Akcje skorygowane to akcje skorygowane o podział.
Sprzedaż insidera BDTX / Black Diamond Therapeutics, Inc. — analiza strat krótkoterminowych
W tej sekcji analizujemy możliwość uniknięcia krótkoterminowych strat w wyniku każdej nieplanowanej sprzedaży poufnych informacji na otwartym rynku dokonanej w ALGS / Aligos Therapeutics, Inc.. Konsekwentny wzorzec unikania strat może sugerować, że przyszłe transakcje sprzedaży mogą przewidywać spadki cen. Analiza ta obejmuje okres jednego roku po każdej transakcji, a wyniki mają charakter teoretyczny .
Poniższa tabela przedstawia najnowsze sprzedaże na otwartym rynku, które nie były częścią planu handlu automatycznego.
| Data transakcji | Ticker | Insider | Zgłoszone Akcje |
Zgłoszona Cena |
Skorygowane Akcje |
Skorygowana Cena |
Podstawa kalkulacji kosztów | Dni do min |
Cena min |
Uniknięta maksymalna strata ($) |
Uniknięta Maksymalna strata (%) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-08-28 | BDTX | Versant Venture Capital VI, L.P. | 221 600 | 6,3202 | 221 600 | 6,3202 | 1 400 556 | 223 | 1.2500 | -1 123 556 | -80,22 |
Cena skorygowana to cena skorygowana o podział. Akcje skorygowane to akcje skorygowane o podział.
Zakupy insidera GLUE / Monte Rosa Therapeutics, Inc. – krótkoterminowa analiza zysków
W tej części analizujemy rentowność każdego nieplanowanego zakupu od poufnych informacji na otwartym rynku dokonanego w ALGS / Aligos Therapeutics, Inc.. Analiza ta pomaga zrozumieć, czy insider konsekwentnie generuje nietypowe zyski i czy warto ją śledzić. Analiza ta obejmuje okres jednego roku po każdej transakcji, a wyniki mają charakter teoretyczny .
Poniższa tabela przedstawia najnowsze zakupy na otwartym rynku, które nie były częścią planu handlu automatycznego.
| Data transakcji | Ticker | Insider | Zgłoszone Akcje |
Zgłoszona Cena |
Skorygowane Akcje |
Skorygowana Cena |
Podstawa kalkulacji kosztów | Dni do maks |
Cena maks |
Maks Zysk ($) |
Maksymalny zwrot (%) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021-06-28 | GLUE | Versant Venture Capital VI, L.P. | 157 895 | 19,0000 | 157 895 | 19,0000 | 3 000 005 | 67 | 42.21 | 3 664 743 | 122,16 |
Cena skorygowana to cena skorygowana o podział. Akcje skorygowane to akcje skorygowane o podział.
Sprzedaż insidera GLUE / Monte Rosa Therapeutics, Inc. — analiza strat krótkoterminowych
W tej sekcji analizujemy możliwość uniknięcia krótkoterminowych strat w wyniku każdej nieplanowanej sprzedaży poufnych informacji na otwartym rynku dokonanej w ALGS / Aligos Therapeutics, Inc.. Konsekwentny wzorzec unikania strat może sugerować, że przyszłe transakcje sprzedaży mogą przewidywać spadki cen. Analiza ta obejmuje okres jednego roku po każdej transakcji, a wyniki mają charakter teoretyczny .
Poniższa tabela przedstawia najnowsze sprzedaże na otwartym rynku, które nie były częścią planu handlu automatycznego.
Cena skorygowana to cena skorygowana o podział. Akcje skorygowane to akcje skorygowane o podział.
Zakupy insidera PASG / Passage Bio, Inc. – krótkoterminowa analiza zysków
W tej części analizujemy rentowność każdego nieplanowanego zakupu od poufnych informacji na otwartym rynku dokonanego w ALGS / Aligos Therapeutics, Inc.. Analiza ta pomaga zrozumieć, czy insider konsekwentnie generuje nietypowe zyski i czy warto ją śledzić. Analiza ta obejmuje okres jednego roku po każdej transakcji, a wyniki mają charakter teoretyczny .
Poniższa tabela przedstawia najnowsze zakupy na otwartym rynku, które nie były częścią planu handlu automatycznego.
| Data transakcji | Ticker | Insider | Zgłoszone Akcje |
Zgłoszona Cena |
Skorygowane Akcje |
Skorygowana Cena |
Podstawa kalkulacji kosztów | Dni do maks |
Cena maks |
Maks Zysk ($) |
Maksymalny zwrot (%) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2020-03-03 | PASG | Versant Venture Capital VI, L.P. | 225 000 | 18,0000 | 11 250 | 360,0000 | 4 050 000 | 112 | 36.07 | -3 644 212 | -89,98 |
Cena skorygowana to cena skorygowana o podział. Akcje skorygowane to akcje skorygowane o podział.
Sprzedaż insidera PASG / Passage Bio, Inc. — analiza strat krótkoterminowych
W tej sekcji analizujemy możliwość uniknięcia krótkoterminowych strat w wyniku każdej nieplanowanej sprzedaży poufnych informacji na otwartym rynku dokonanej w ALGS / Aligos Therapeutics, Inc.. Konsekwentny wzorzec unikania strat może sugerować, że przyszłe transakcje sprzedaży mogą przewidywać spadki cen. Analiza ta obejmuje okres jednego roku po każdej transakcji, a wyniki mają charakter teoretyczny .
Poniższa tabela przedstawia najnowsze sprzedaże na otwartym rynku, które nie były częścią planu handlu automatycznego.
| Data transakcji | Ticker | Insider | Zgłoszone Akcje |
Zgłoszona Cena |
Skorygowane Akcje |
Skorygowana Cena |
Podstawa kalkulacji kosztów | Dni do min |
Cena min |
Uniknięta maksymalna strata ($) |
Uniknięta Maksymalna strata (%) |
|---|---|---|---|---|---|---|---|
| Nie znane są żadne nieplanowane transakcje na otwarttm rynku dla tej kombinacji insidera i papieru wartościowego |
Cena skorygowana to cena skorygowana o podział. Akcje skorygowane to akcje skorygowane o podział.
Historia handlu insiderów
Ta tabela przedstawia pełną listę transakcji insiderów dokonanych przez firmę Versant Vantage I, L.P. ujawnioną Komisji Papierów Wartościowych (SEC).
| Data pliku | Data trans | Formularz | Ticker | Bezpieczeństwo | Kod | Akcje | Pozostałe akcje | Zmiana procent |
Cena udziału |
Wartość trans |
Pozostała Wartość |
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-09-23 |
|
4 | LVTX |
LAVA Therapeutics NV
Common Stock |
S - Sale | -532 870 | 0 | -100,00 | 1,40 | -746 764 | ||
| 2025-09-23 |
|
4 | LVTX |
LAVA Therapeutics NV
Common Stock |
S - Sale | -2 370 533 | 0 | -100,00 | 1,40 | -3 322 065 | ||
| 2025-09-18 |
|
4 | LVTX |
LAVA Therapeutics NV
Common Stock |
S - Sale | -228 791 | 532 870 | -30,04 | 1,44 | -329 871 | 768 292 | |
| 2025-09-18 |
|
4 | LVTX |
LAVA Therapeutics NV
Common Stock |
S - Sale | -366 111 | 2 370 533 | -13,38 | 1,44 | -527 859 | 3 417 834 | |
| 2025-09-18 |
|
4 | LVTX |
LAVA Therapeutics NV
Common Stock |
S - Sale | -226 726 | 761 661 | -22,94 | 1,49 | -337 640 | 1 134 266 | |
| 2025-09-18 |
|
4 | LVTX |
LAVA Therapeutics NV
Common Stock |
S - Sale | -362 806 | 2 736 644 | -11,71 | 1,49 | -540 291 | 4 075 410 | |
| 2025-09-18 |
|
4 | LVTX |
LAVA Therapeutics NV
Common Stock |
S - Sale | -192 293 | 988 387 | -16,29 | 1,53 | -294 824 | 1 515 395 | |
| 2025-09-18 |
|
4 | LVTX |
LAVA Therapeutics NV
Common Stock |
S - Sale | -307 707 | 3 099 450 | -9,03 | 1,53 | -471 776 | 4 752 077 | |
| 2025-02-06 | 3 | LVTX |
LAVA Therapeutics NV
Common Shares |
3 407 157 | ||||||||
| 2025-02-06 | 3 | LVTX |
LAVA Therapeutics NV
Common Shares |
1 180 680 | ||||||||
| 2024-10-30 |
|
4 | GLUE |
Monte Rosa Therapeutics, Inc.
Common Stock |
S - Sale | -15 600 | 1 573 453 | -0,98 | 9,41 | -146 793 | 14 805 878 | |
| 2024-10-30 |
|
4 | GLUE |
Monte Rosa Therapeutics, Inc.
Common Stock |
S - Sale | -52 305 | 1 589 053 | -3,19 | 9,08 | -475 008 | 14 430 985 | |
| 2024-10-30 |
|
4 | GLUE |
Monte Rosa Therapeutics, Inc.
Common Stock |
J - Other | -5 454 | 0 | -100,00 | ||||
| 2024-10-30 |
|
4 | GLUE |
Monte Rosa Therapeutics, Inc.
Common Stock |
J - Other | 5 454 | 5 454 | |||||
| 2024-10-30 |
|
4 | GLUE |
Monte Rosa Therapeutics, Inc.
Common Stock |
J - Other | -5 499 | 0 | -100,00 | ||||
| 2024-10-30 |
|
4 | GLUE |
Monte Rosa Therapeutics, Inc.
Common Stock |
J - Other | 5 499 | 5 499 | |||||
| 2024-10-30 |
|
4 | GLUE |
Monte Rosa Therapeutics, Inc.
Common Stock |
J - Other | -366 590 | 1 641 358 | -18,26 | ||||
| 2024-10-30 |
|
4 | GLUE |
Monte Rosa Therapeutics, Inc.
Common Stock |
J - Other | -17 595 | 0 | -100,00 | ||||
| 2024-10-30 |
|
4 | GLUE |
Monte Rosa Therapeutics, Inc.
Common Stock |
J - Other | 17 595 | 17 595 | |||||
| 2024-10-30 |
|
4 | GLUE |
Monte Rosa Therapeutics, Inc.
Common Stock |
J - Other | -20 397 | 0 | -100,00 | ||||
| 2024-10-30 |
|
4 | GLUE |
Monte Rosa Therapeutics, Inc.
Common Stock |
J - Other | 20 397 | 20 397 | |||||
| 2024-10-30 |
|
4 | GLUE |
Monte Rosa Therapeutics, Inc.
Common Stock |
J - Other | -1 019 867 | 4 079 469 | -20,00 | ||||
| 2024-10-30 |
|
4 | GLUE |
Monte Rosa Therapeutics, Inc.
Common Stock |
S - Sale | -89 990 | 2 007 948 | -4,29 | 9,66 | -869 240 | 19 395 372 | |
| 2024-09-24 |
|
4 | GLUE |
Monte Rosa Therapeutics, Inc.
Common Stock |
S - Sale | -1 132 566 | 5 099 336 | -18,17 | 6,53 | -7 395 203 | 33 296 624 | |
| 2024-09-13 |
|
4 | GLUE |
Monte Rosa Therapeutics, Inc.
Common Stock |
S - Sale | -9 269 | 6 231 902 | -0,15 | 6,16 | -57 100 | 38 390 386 | |
| 2024-09-13 |
|
4 | GLUE |
Monte Rosa Therapeutics, Inc.
Common Stock |
S - Sale | -16 047 | 6 241 171 | -0,26 | 6,00 | -96 309 | 37 457 636 | |
| 2024-09-13 |
|
4 | GLUE |
Monte Rosa Therapeutics, Inc.
Common Stock |
S - Sale | -541 897 | 6 257 218 | -7,97 | 6,00 | -3 251 382 | 37 543 308 | |
| 2024-08-30 |
|
4 | BDTX |
Black Diamond Therapeutics, Inc.
Common Stock |
S - Sale | -221 600 | 3 726 341 | -5,61 | 6,32 | -1 400 556 | 23 551 220 | |
| 2024-04-11 |
|
4 | CTNM |
Contineum Therapeutics, Inc.
Class A Common Stock |
C - Conversion | 148 312 | 148 312 | |||||
| 2024-04-11 |
|
4 | CTNM |
Contineum Therapeutics, Inc.
Class A Common Stock |
C - Conversion | 2 531 | 2 531 | |||||
| 2024-04-11 |
|
4 | CTNM |
Contineum Therapeutics, Inc.
Class A Common Stock |
C - Conversion | 391 785 | 391 785 | |||||
| 2024-04-04 | 3 | CTNM |
Contineum Therapeutics, Inc.
Class A Common Stock |
375 535 | ||||||||
| 2023-01-04 |
|
4 | OYST |
Oyster Point Pharma, Inc.
Common Stock |
U - Other | -1 003 658 | 0 | -100,00 | ||||
| 2023-01-04 |
|
4 | OYST |
Oyster Point Pharma, Inc.
Common Stock |
U - Other | -2 465 | 0 | -100,00 | ||||
| 2023-01-04 |
|
4 | OYST |
Oyster Point Pharma, Inc.
Common Stock |
U - Other | -414 607 | 0 | -100,00 | ||||
| 2023-01-04 |
|
4 | OYST |
Oyster Point Pharma, Inc.
Common Stock |
U - Other | -2 236 888 | 0 | -100,00 | ||||
| 2022-06-07 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
J - Other | -10 099 | 0 | -100,00 | ||||
| 2022-06-07 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
J - Other | 10 099 | 10 099 | |||||
| 2022-06-07 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
J - Other | -46 753 | 64 731 | -41,94 | ||||
| 2022-06-07 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
J - Other | -141 103 | 0 | -100,00 | ||||
| 2022-06-07 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
J - Other | 4 419 | 141 103 | 3,23 | ||||
| 2022-06-07 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
J - Other | -20 454 | 28 322 | -41,93 | ||||
| 2022-06-07 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
J - Other | 3 992 | 136 684 | 3,01 | ||||
| 2022-06-07 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
J - Other | -18 478 | 25 587 | -41,93 | ||||
| 2022-06-07 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
J - Other | 132 692 | 132 692 | |||||
| 2022-06-07 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
J - Other | -614 315 | 850 560 | -41,94 | ||||
| 2022-06-07 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
S - Sale | -33 395 | 111 484 | -23,05 | 12,25 | -409 146 | 1 365 869 | |
| 2022-06-07 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
S - Sale | -14 611 | 48 776 | -23,05 | 12,25 | -179 010 | 597 589 | |
| 2022-06-07 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
S - Sale | -13 199 | 44 065 | -23,05 | 12,25 | -161 710 | 539 871 | |
| 2022-06-07 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
S - Sale | -438 795 | 1 464 875 | -23,05 | 12,25 | -5 375 985 | 17 947 209 | |
| 2022-06-07 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
S - Sale | -250 000 | 2 344 451 | -9,64 | 12,25 | -3 062 925 | 28 723 510 | |
| 2022-01-07 |
|
4 | OYST |
Oyster Point Pharma, Inc.
Common Stock |
J - Other | X | -1 261 | 2 465 | -33,84 | |||
| 2022-01-07 |
|
4 | OYST |
Oyster Point Pharma, Inc.
Common Stock |
J - Other | -51 556 | 0 | -100,00 | ||||
| 2022-01-07 |
|
4 | OYST |
Oyster Point Pharma, Inc.
Common Stock |
J - Other | 51 556 | 51 556 | |||||
| 2022-01-07 |
|
4 | OYST |
Oyster Point Pharma, Inc.
Common Stock |
J - Other | X | -200 213 | 414 607 | -32,56 | |||
| 2021-12-23 |
|
4 | OYST |
Oyster Point Pharma, Inc.
Common Stock |
J - Other | X | -1 261 | 3 726 | -25,29 | |||
| 2021-12-23 |
|
4 | OYST |
Oyster Point Pharma, Inc.
Common Stock |
J - Other | -51 556 | 0 | -100,00 | ||||
| 2021-12-23 |
|
4 | OYST |
Oyster Point Pharma, Inc.
Common Stock |
J - Other | 51 556 | 51 556 | |||||
| 2021-12-23 |
|
4 | OYST |
Oyster Point Pharma, Inc.
Common Stock |
J - Other | X | -200 213 | 614 820 | -24,57 | |||
| 2021-10-20 |
|
4 | OYST |
Oyster Point Pharma, Inc.
Common Stock |
S - Sale | X | -1 531 | 4 987 | -23,49 | 15,09 | -23 109 | 75 273 |
| 2021-10-20 |
|
4 | OYST |
Oyster Point Pharma, Inc.
Common Stock |
S - Sale | X | -242 943 | 815 033 | -22,96 | 15,09 | -3 666 957 | 12 302 027 |
| 2021-10-20 |
|
4 | OYST |
Oyster Point Pharma, Inc.
Common Stock |
S - Sale | X | -1 912 | 6 518 | -22,68 | 14,63 | -27 978 | 95 376 |
| 2021-10-20 |
|
4 | OYST |
Oyster Point Pharma, Inc.
Common Stock |
S - Sale | X | -303 614 | 1 057 976 | -22,30 | 14,63 | -4 442 693 | 15 481 045 |
| 2021-08-09 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
J - Other | -2 260 | 0 | -100,00 | ||||
| 2021-08-09 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
J - Other | 2 260 | 2 260 | |||||
| 2021-08-09 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
J - Other | -2 279 | 0 | -100,00 | ||||
| 2021-08-09 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
J - Other | 2 279 | 2 279 | |||||
| 2021-08-09 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
J - Other | X | -152 071 | 231 211 | -39,68 | |||
| 2021-06-30 |
|
4 | GLUE |
Monte Rosa Therapeutics, Inc.
Series C convertible preferred stock |
C - Conversion | -2 699 328 | 0 | -100,00 | ||||
| 2021-06-30 |
|
4 | GLUE |
Monte Rosa Therapeutics, Inc.
Series B convertible preferred stock |
C - Conversion | -4 150 000 | 0 | -100,00 | ||||
| 2021-06-30 |
|
4 | GLUE |
Monte Rosa Therapeutics, Inc.
Series B convertible preferred stock |
C - Conversion | -3 000 000 | 0 | -100,00 | ||||
| 2021-06-30 |
|
4 | GLUE |
Monte Rosa Therapeutics, Inc.
Series A convertible preferred stock |
C - Conversion | -20 004 280 | 0 | -100,00 | ||||
| 2021-06-30 |
|
4 | GLUE |
Monte Rosa Therapeutics, Inc.
Common Stock |
P - Purchase | 157 895 | 2 097 938 | 8,14 | 19,00 | 3 000 005 | 39 860 822 | |
| 2021-06-30 |
|
4 | GLUE |
Monte Rosa Therapeutics, Inc.
Common Stock |
C - Conversion | 1 940 043 | 1 940 043 | |||||
| 2021-06-30 |
|
4 | GLUE |
Monte Rosa Therapeutics, Inc.
Common Stock |
C - Conversion | 6 515 869 | 6 799 115 | 2 300,43 | ||||
| 2021-06-23 | 3 | GLUE |
Monte Rosa Therapeutics, Inc.
Common Stock |
283 246 | ||||||||
| 2021-06-03 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
J - Other | -1 119 | 0 | -100,00 | ||||
| 2021-06-03 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
J - Other | 1 119 | 1 119 | |||||
| 2021-06-03 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
J - Other | -1 128 | 0 | -100,00 | ||||
| 2021-06-03 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
J - Other | 1 128 | 1 128 | |||||
| 2021-06-03 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
J - Other | -75 000 | 383 282 | -16,37 | ||||
| 2021-05-14 |
|
4 | OYST |
Oyster Point Pharma, Inc.
Common Stock |
J - Other | -2 018 | 8 430 | -19,31 | ||||
| 2021-05-14 |
|
4 | OYST |
Oyster Point Pharma, Inc.
Common Stock |
J - Other | -82 486 | 0 | -100,00 | ||||
| 2021-05-14 |
|
4 | OYST |
Oyster Point Pharma, Inc.
Common Stock |
J - Other | 82 486 | 82 486 | |||||
| 2021-05-14 |
|
4 | OYST |
Oyster Point Pharma, Inc.
Common Stock |
J - Other | -320 340 | 1 361 590 | -19,05 | ||||
| 2021-05-07 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
J - Other | -3 473 | 0 | -100,00 | ||||
| 2021-05-07 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
J - Other | 3 473 | 3 473 | |||||
| 2021-05-07 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
J - Other | X | -16 079 | 144 879 | -9,99 | |||
| 2021-05-07 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
J - Other | -48 528 | 0 | -100,00 | ||||
| 2021-05-07 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
J - Other | 1 520 | 48 528 | 3,23 | ||||
| 2021-05-07 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
J - Other | X | -7 035 | 63 387 | -9,99 | |||
| 2021-05-07 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
J - Other | 1 373 | 47 008 | 3,01 | ||||
| 2021-05-07 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
J - Other | X | -6 355 | 57 264 | -9,99 | |||
| 2021-05-07 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
J - Other | 45 635 | 45 635 | |||||
| 2021-05-07 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
J - Other | X | -211 277 | 1 903 670 | -9,99 | |||
| 2021-03-30 |
|
4 | OYST |
Oyster Point Pharma, Inc.
Common Stock |
J - Other | -1 990 | 10 448 | -16,00 | ||||
| 2021-03-30 |
|
4 | OYST |
Oyster Point Pharma, Inc.
Common Stock |
J - Other | -82 491 | 0 | -100,00 | ||||
| 2021-03-30 |
|
4 | OYST |
Oyster Point Pharma, Inc.
Common Stock |
J - Other | 82 491 | 82 491 | |||||
| 2021-03-30 |
|
4 | OYST |
Oyster Point Pharma, Inc.
Common Stock |
J - Other | -320 368 | 1 681 930 | -16,00 | ||||
| 2021-02-19 |
|
4 | OYST |
Oyster Point Pharma, Inc.
Common Stock |
J - Other | -5 607 | 0 | -100,00 | ||||
| 2021-02-19 |
|
4 | OYST |
Oyster Point Pharma, Inc.
Common Stock |
J - Other | 5 607 | 5 607 | |||||
| 2021-02-19 |
|
4 | OYST |
Oyster Point Pharma, Inc.
Common Stock |
J - Other | -6 500 | 0 | -100,00 | ||||
| 2021-02-19 |
|
4 | OYST |
Oyster Point Pharma, Inc.
Common Stock |
J - Other | 6 500 | 6 500 | |||||
| 2021-02-19 |
|
4 | OYST |
Oyster Point Pharma, Inc.
Common Stock |
J - Other | X | -325 000 | 2 236 888 | -12,69 | |||
| 2021-02-18 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
J - Other | -745 | 0 | -100,00 | ||||
| 2021-02-18 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
J - Other | 745 | 745 | |||||
| 2021-02-18 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
J - Other | -751 | 0 | -100,00 | ||||
| 2021-02-18 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
J - Other | 751 | 751 | |||||
| 2021-02-18 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
J - Other | X | -50 000 | 458 282 | -9,84 | |||
| 2021-02-18 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
J - Other | -5 176 | 0 | -100,00 | ||||
| 2021-02-18 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
J - Other | 5 176 | 5 176 | |||||
| 2021-02-18 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
J - Other | -6 000 | 0 | -100,00 | ||||
| 2021-02-18 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
J - Other | 6 000 | 6 000 | |||||
| 2021-02-18 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
J - Other | X | -300 000 | 2 594 451 | -10,36 | |||
| 2021-02-02 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
J - Other | -745 | 0 | -100,00 | ||||
| 2021-02-02 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
J - Other | 745 | 745 | |||||
| 2021-02-02 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
J - Other | -751 | 0 | -100,00 | ||||
| 2021-02-02 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
J - Other | 751 | 751 | |||||
| 2021-02-02 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
J - Other | X | -50 000 | 508 282 | -8,96 | |||
| 2021-02-02 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
J - Other | -4 313 | 0 | -100,00 | ||||
| 2021-02-02 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
J - Other | 4 313 | 4 313 | |||||
| 2021-02-02 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
J - Other | -5 000 | 0 | -100,00 | ||||
| 2021-02-02 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
J - Other | 5 000 | 5 000 | |||||
| 2021-02-02 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
J - Other | X | -250 000 | 2 894 451 | -7,95 | |||
| 2021-02-02 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
J - Other | -4 328 | 0 | -100,00 | ||||
| 2021-02-02 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
J - Other | 4 328 | 4 328 | |||||
| 2021-02-02 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
J - Other | X | -20 037 | 160 958 | -11,07 | |||
| 2021-02-02 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
J - Other | -60 472 | 0 | -100,00 | ||||
| 2021-02-02 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
J - Other | 1 893 | 60 472 | 3,23 | ||||
| 2021-02-02 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
J - Other | X | -8 766 | 70 422 | -11,07 | |||
| 2021-02-02 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
J - Other | 1 711 | 58 579 | 3,01 | ||||
| 2021-02-02 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
J - Other | X | -7 919 | 63 619 | -11,07 | |||
| 2021-02-02 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
J - Other | 56 868 | 56 868 | |||||
| 2021-02-02 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
J - Other | X | -263 278 | 2 114 947 | -11,07 | |||
| 2021-01-19 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
J - Other | -745 | 0 | -100,00 | ||||
| 2021-01-19 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
J - Other | 745 | 745 | |||||
| 2021-01-19 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
J - Other | -751 | 0 | -100,00 | ||||
| 2021-01-19 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
J - Other | 751 | 751 | |||||
| 2021-01-19 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
J - Other | X | -50 000 | 558 282 | -8,22 | |||
| 2021-01-19 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
J - Other | -4 744 | 0 | -100,00 | ||||
| 2021-01-19 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
J - Other | 4 744 | 4 744 | |||||
| 2021-01-19 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
J - Other | -5 500 | 0 | -100,00 | ||||
| 2021-01-19 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
J - Other | 5 500 | 5 500 | |||||
| 2021-01-19 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
J - Other | X | -275 000 | 3 144 451 | -8,04 | |||
| 2021-01-19 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
J - Other | -1 388 | 0 | -100,00 | ||||
| 2021-01-19 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
J - Other | 1 388 | 1 388 | |||||
| 2021-01-19 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
J - Other | X | -11 688 | 180 995 | -6,07 | |||
| 2021-01-19 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
J - Other | -35 276 | 0 | -100,00 | ||||
| 2021-01-19 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
J - Other | 1 105 | 35 276 | 3,23 | ||||
| 2021-01-19 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
J - Other | X | -5 113 | 79 188 | -6,07 | |||
| 2021-01-19 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
J - Other | 998 | 34 171 | 3,01 | ||||
| 2021-01-19 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
J - Other | X | -4 620 | 71 538 | -6,07 | |||
| 2021-01-19 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
J - Other | 33 173 | 33 173 | |||||
| 2021-01-19 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
J - Other | X | -153 579 | 2 378 225 | -6,07 | |||
| 2020-12-17 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
J - Other | X | -21 707 | 192 683 | -10,13 | |||
| 2020-12-17 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
J - Other | X | -9 497 | 84 301 | -10,12 | |||
| 2020-12-17 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
J - Other | X | -8 579 | 76 158 | -10,12 | |||
| 2020-12-17 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
J - Other | X | -285 217 | 2 531 804 | -10,12 | |||
| 2020-12-16 |
|
4 | BDTX |
Black Diamond Therapeutics, Inc.
Common Stock |
J - Other | -307 | 0 | -100,00 | ||||
| 2020-12-16 |
|
4 | BDTX |
Black Diamond Therapeutics, Inc.
Common Stock |
J - Other | 307 | 307 | |||||
| 2020-12-16 |
|
4 | BDTX |
Black Diamond Therapeutics, Inc.
Common Stock |
J - Other | -310 | 0 | -100,00 | ||||
| 2020-12-16 |
|
4 | BDTX |
Black Diamond Therapeutics, Inc.
Common Stock |
J - Other | 310 | 310 | |||||
| 2020-12-16 |
|
4 | BDTX |
Black Diamond Therapeutics, Inc.
Common Stock |
J - Other | X | -20 784 | 822 140 | -2,47 | |||
| 2020-12-01 |
|
4 | BDTX |
Black Diamond Therapeutics, Inc.
Common Stock |
J - Other | -463 | 0 | -100,00 | ||||
| 2020-12-01 |
|
4 | BDTX |
Black Diamond Therapeutics, Inc.
Common Stock |
J - Other | 463 | 463 | |||||
| 2020-12-01 |
|
4 | BDTX |
Black Diamond Therapeutics, Inc.
Common Stock |
J - Other | -467 | 0 | -100,00 | ||||
| 2020-12-01 |
|
4 | BDTX |
Black Diamond Therapeutics, Inc.
Common Stock |
J - Other | 467 | 467 | |||||
| 2020-12-01 |
|
4 | BDTX |
Black Diamond Therapeutics, Inc.
Common Stock |
J - Other | X | -31 175 | 842 924 | -3,57 | |||
| 2020-12-01 |
|
4 | BDTX |
Black Diamond Therapeutics, Inc.
Common Stock |
S - Sale | X | -200 | 874 099 | -0,02 | 34,16 | -6 833 | 29 863 243 |
| 2020-12-01 |
|
4 | BDTX |
Black Diamond Therapeutics, Inc.
Common Stock |
S - Sale | X | -10 193 | 874 299 | -1,15 | 33,13 | -337 680 | 28 964 302 |
| 2020-12-01 |
|
4 | BDTX |
Black Diamond Therapeutics, Inc.
Common Stock |
J - Other | -6 797 | 0 | -100,00 | ||||
| 2020-12-01 |
|
4 | BDTX |
Black Diamond Therapeutics, Inc.
Common Stock |
J - Other | 6 797 | 6 797 | |||||
| 2020-12-01 |
|
4 | BDTX |
Black Diamond Therapeutics, Inc.
Common Stock |
J - Other | -7 880 | 0 | -100,00 | ||||
| 2020-12-01 |
|
4 | BDTX |
Black Diamond Therapeutics, Inc.
Common Stock |
J - Other | 7 880 | 7 880 | |||||
| 2020-12-01 |
|
4 | BDTX |
Black Diamond Therapeutics, Inc.
Common Stock |
J - Other | -394 000 | 3 947 941 | -9,07 | ||||
| 2020-11-25 |
|
4 | BDTX |
Black Diamond Therapeutics, Inc.
Common Stock |
J - Other | -3 316 | 0 | -100,00 | ||||
| 2020-11-25 |
|
4 | BDTX |
Black Diamond Therapeutics, Inc.
Common Stock |
J - Other | 2 488 | 3 316 | 300,48 | ||||
| 2020-11-25 |
|
4 | BDTX |
Black Diamond Therapeutics, Inc.
Common Stock |
J - Other | -46 121 | 380 942 | -10,80 | ||||
| 2020-11-25 |
|
4 | BDTX |
Black Diamond Therapeutics, Inc.
Common Stock |
J - Other | 828 | 828 | |||||
| 2020-11-25 |
|
4 | BDTX |
Black Diamond Therapeutics, Inc.
Common Stock |
J - Other | -154 671 | 1 277 541 | -10,80 | ||||
| 2020-11-25 |
|
4 | BDTX |
Black Diamond Therapeutics, Inc.
Common Stock |
J - Other | -1 258 | 0 | -100,00 | ||||
| 2020-11-25 |
|
4 | BDTX |
Black Diamond Therapeutics, Inc.
Common Stock |
J - Other | 1 258 | 1 258 | |||||
| 2020-11-25 |
|
4 | BDTX |
Black Diamond Therapeutics, Inc.
Common Stock |
J - Other | -1 269 | 0 | -100,00 | ||||
| 2020-11-25 |
|
4 | BDTX |
Black Diamond Therapeutics, Inc.
Common Stock |
J - Other | 1 269 | 1 269 | |||||
| 2020-11-25 |
|
4 | BDTX |
Black Diamond Therapeutics, Inc.
Common Stock |
J - Other | -84 462 | 884 492 | -8,72 | ||||
| 2020-11-25 |
|
4 | BDTX |
Black Diamond Therapeutics, Inc.
Common Stock |
J - Other | -8 223 | 0 | -100,00 | ||||
| 2020-11-25 |
|
4 | BDTX |
Black Diamond Therapeutics, Inc.
Common Stock |
J - Other | 8 223 | 8 223 | |||||
| 2020-11-25 |
|
4 | BDTX |
Black Diamond Therapeutics, Inc.
Common Stock |
J - Other | -9 533 | 0 | -100,00 | ||||
| 2020-11-25 |
|
4 | BDTX |
Black Diamond Therapeutics, Inc.
Common Stock |
J - Other | 9 533 | 9 533 | |||||
| 2020-11-25 |
|
4 | BDTX |
Black Diamond Therapeutics, Inc.
Common Stock |
J - Other | -476 659 | 4 341 941 | -9,89 | ||||
| 2020-11-23 |
|
4 | BDTX |
Black Diamond Therapeutics, Inc.
Common Stock |
S - Sale | X | -114 854 | 4 818 600 | -2,33 | 33,01 | -3 791 331 | 159 061 986 |
| 2020-11-23 |
|
4 | BDTX |
Black Diamond Therapeutics, Inc.
Common Stock |
S - Sale | X | -15 163 | 968 954 | -1,54 | 33,01 | -500 531 | 31 985 172 |
| 2020-11-19 |
|
4 | BDTX |
Black Diamond Therapeutics, Inc.
Common Stock |
S - Sale | X | -473 | 4 933 454 | -0,01 | 33,09 | -15 653 | 163 266 740 |
| 2020-11-19 |
|
4 | BDTX |
Black Diamond Therapeutics, Inc.
Common Stock |
S - Sale | X | -63 | 984 117 | -0,01 | 33,09 | -2 085 | 32 568 171 |
| 2020-11-19 |
|
4 | BDTX |
Black Diamond Therapeutics, Inc.
Common Stock |
S - Sale | X | -3 705 | 4 933 927 | -0,08 | 33,05 | -122 450 | 163 065 301 |
| 2020-11-19 |
|
4 | BDTX |
Black Diamond Therapeutics, Inc.
Common Stock |
S - Sale | X | -489 | 984 180 | -0,05 | 33,05 | -16 161 | 32 526 952 |
| 2020-11-17 |
|
4 | BDTX |
Black Diamond Therapeutics, Inc.
Common Stock |
S - Sale | X | -177 | 4 937 632 | 0,00 | 33,01 | -5 843 | 163 003 576 |
| 2020-11-17 |
|
4 | BDTX |
Black Diamond Therapeutics, Inc.
Common Stock |
S - Sale | X | -23 | 984 669 | 0,00 | 33,01 | -759 | 32 506 385 |
| 2020-11-17 |
|
4 | BDTX |
Black Diamond Therapeutics, Inc.
Common Stock |
S - Sale | X | -1 502 | 4 937 809 | -0,03 | 34,53 | -51 865 | 170 506 989 |
| 2020-11-17 |
|
4 | BDTX |
Black Diamond Therapeutics, Inc.
Common Stock |
S - Sale | X | -2 473 | 4 939 311 | -0,05 | 33,31 | -82 388 | 164 552 652 |
| 2020-11-17 |
|
4 | BDTX |
Black Diamond Therapeutics, Inc.
Common Stock |
S - Sale | X | -198 | 984 692 | -0,02 | 34,53 | -6 837 | 34 002 301 |
| 2020-11-17 |
|
4 | BDTX |
Black Diamond Therapeutics, Inc.
Common Stock |
S - Sale | X | -327 | 984 890 | -0,03 | 33,31 | -10 894 | 32 811 512 |
| 2020-11-13 |
|
4 | BDTX |
Black Diamond Therapeutics, Inc.
Common Stock |
S - Sale | X | -353 | 4 941 784 | -0,01 | 35,15 | -12 408 | 173 697 777 |
| 2020-11-13 |
|
4 | BDTX |
Black Diamond Therapeutics, Inc.
Common Stock |
S - Sale | X | -9 450 | 4 942 137 | -0,19 | 34,39 | -325 012 | 169 973 929 |
| 2020-11-13 |
|
4 | BDTX |
Black Diamond Therapeutics, Inc.
Common Stock |
S - Sale | X | -3 976 | 4 951 587 | -0,08 | 33,48 | -133 106 | 165 766 259 |
| 2020-11-13 |
|
4 | BDTX |
Black Diamond Therapeutics, Inc.
Common Stock |
S - Sale | X | -47 | 985 217 | 0,00 | 35,15 | -1 652 | 34 629 195 |
| 2020-11-13 |
|
4 | BDTX |
Black Diamond Therapeutics, Inc.
Common Stock |
S - Sale | X | -1 248 | 985 264 | -0,13 | 34,39 | -42 922 | 33 885 988 |
| 2020-11-13 |
|
4 | BDTX |
Black Diamond Therapeutics, Inc.
Common Stock |
S - Sale | X | -524 | 986 512 | -0,05 | 33,48 | -17 542 | 33 025 857 |
| 2020-11-13 |
|
4 | BDTX |
Black Diamond Therapeutics, Inc.
Common Stock |
J - Other | -4 282 | 0 | -100,00 | ||||
| 2020-11-13 |
|
4 | BDTX |
Black Diamond Therapeutics, Inc.
Common Stock |
J - Other | 3 211 | 4 282 | 299,81 | ||||
| 2020-11-13 |
|
4 | BDTX |
Black Diamond Therapeutics, Inc.
Common Stock |
J - Other | -59 534 | 427 063 | -12,23 | ||||
| 2020-11-13 |
|
4 | BDTX |
Black Diamond Therapeutics, Inc.
Common Stock |
J - Other | 1 071 | 1 071 | |||||
| 2020-11-13 |
|
4 | BDTX |
Black Diamond Therapeutics, Inc.
Common Stock |
J - Other | -199 652 | 1 432 212 | -12,23 | ||||
| 2020-11-13 |
|
4 | BDTX |
Black Diamond Therapeutics, Inc.
Common Stock |
J - Other | -11 918 | 0 | -100,00 | ||||
| 2020-11-13 |
|
4 | BDTX |
Black Diamond Therapeutics, Inc.
Common Stock |
J - Other | 11 918 | 11 918 | |||||
| 2020-11-13 |
|
4 | BDTX |
Black Diamond Therapeutics, Inc.
Common Stock |
J - Other | -13 816 | 0 | -100,00 | ||||
| 2020-11-13 |
|
4 | BDTX |
Black Diamond Therapeutics, Inc.
Common Stock |
J - Other | 13 816 | 13 816 | |||||
| 2020-11-13 |
|
4 | BDTX |
Black Diamond Therapeutics, Inc.
Common Stock |
J - Other | -690 814 | 4 955 563 | -12,23 | ||||
| 2020-11-12 |
|
4 | BDTX |
Black Diamond Therapeutics, Inc.
Common Stock |
S - Sale | X | -9 027 | 5 646 377 | -0,16 | 34,94 | -315 378 | 197 268 603 |
| 2020-11-12 |
|
4 | BDTX |
Black Diamond Therapeutics, Inc.
Common Stock |
S - Sale | X | -2 119 | 5 655 404 | -0,04 | 33,86 | -71 748 | 191 489 717 |
| 2020-11-12 |
|
4 | BDTX |
Black Diamond Therapeutics, Inc.
Common Stock |
S - Sale | X | -1 191 | 987 036 | -0,12 | 34,94 | -41 610 | 34 484 274 |
| 2020-11-12 |
|
4 | BDTX |
Black Diamond Therapeutics, Inc.
Common Stock |
S - Sale | X | -280 | 988 227 | -0,03 | 33,86 | -9 481 | 33 460 971 |
| 2020-11-12 |
|
4 | BDTX |
Black Diamond Therapeutics, Inc.
Common Stock |
S - Sale | X | -12 433 | 5 657 523 | -0,22 | 34,14 | -424 510 | 193 169 334 |
| 2020-11-12 |
|
4 | BDTX |
Black Diamond Therapeutics, Inc.
Common Stock |
S - Sale | X | -11 388 | 5 669 956 | -0,20 | 33,48 | -381 245 | 189 817 653 |
| 2020-11-12 |
|
4 | BDTX |
Black Diamond Therapeutics, Inc.
Common Stock |
S - Sale | X | -1 642 | 988 507 | -0,17 | 34,14 | -56 064 | 33 751 385 |
| 2020-11-12 |
|
4 | BDTX |
Black Diamond Therapeutics, Inc.
Common Stock |
S - Sale | X | -1 503 | 990 149 | -0,15 | 33,48 | -50 317 | 33 148 010 |
| 2020-11-10 |
|
4 | BDTX |
Black Diamond Therapeutics, Inc.
Common Stock |
S - Sale | X | -5 565 | 5 681 344 | -0,10 | 33,06 | -183 954 | 187 800 235 |
| 2020-11-10 |
|
4 | BDTX |
Black Diamond Therapeutics, Inc.
Common Stock |
S - Sale | X | -735 | 991 652 | -0,07 | 33,06 | -24 296 | 32 779 652 |
| 2020-11-10 |
|
4 | BDTX |
Black Diamond Therapeutics, Inc.
Common Stock |
S - Sale | X | -2 738 | 5 686 909 | -0,05 | 33,13 | -90 706 | 188 398 765 |
| 2020-11-10 |
|
4 | BDTX |
Black Diamond Therapeutics, Inc.
Common Stock |
S - Sale | X | -362 | 992 387 | -0,04 | 33,13 | -11 993 | 32 876 293 |
| 2020-11-06 |
|
4 | BDTX |
Black Diamond Therapeutics, Inc.
Common Stock |
S - Sale | X | -7 816 | 5 689 647 | -0,14 | 33,15 | -259 079 | 188 596 436 |
| 2020-11-06 |
|
4 | BDTX |
Black Diamond Therapeutics, Inc.
Common Stock |
S - Sale | X | -1 032 | 992 749 | -0,10 | 33,15 | -34 208 | 32 906 949 |
| 2020-11-06 |
|
4 | BDTX |
Black Diamond Therapeutics, Inc.
Common Stock |
S - Sale | X | -2 208 | 5 697 463 | -0,04 | 33,14 | -73 164 | 188 789 425 |
| 2020-11-06 |
|
4 | BDTX |
Black Diamond Therapeutics, Inc.
Common Stock |
S - Sale | X | -292 | 993 781 | -0,03 | 33,14 | -9 676 | 32 929 629 |
| 2020-10-28 |
|
4 | BDTX |
Black Diamond Therapeutics, Inc.
Common Stock |
S - Sale | X | -707 | 5 699 671 | -0,01 | 33,03 | -23 354 | 188 274 382 |
| 2020-10-28 |
|
4 | BDTX |
Black Diamond Therapeutics, Inc.
Common Stock |
S - Sale | X | -93 | 994 073 | -0,01 | 33,03 | -3 072 | 32 836 716 |
| 2020-10-28 |
|
4 | BDTX |
Black Diamond Therapeutics, Inc.
Common Stock |
S - Sale | X | -7 158 | 5 700 378 | -0,13 | 33,30 | -238 394 | 189 848 809 |
| 2020-10-28 |
|
4 | BDTX |
Black Diamond Therapeutics, Inc.
Common Stock |
S - Sale | X | -945 | 994 166 | -0,09 | 33,30 | -31 473 | 33 110 301 |
| 2020-10-20 |
|
4 | ALGS |
Aligos Therapeutics, Inc.
Series B-2 Preferred Stock |
C - Conversion | -198 485 | 0 | -100,00 | ||||
| 2020-10-20 |
|
4 | ALGS |
Aligos Therapeutics, Inc.
Series B-2 Preferred Stock |
C - Conversion | -85 065 | 0 | -100,00 | ||||
| 2020-10-20 |
|
4 | ALGS |
Aligos Therapeutics, Inc.
Series B-1 Preferred Stock |
C - Conversion | -463 959 | 0 | -100,00 | ||||
| 2020-10-20 |
|
4 | ALGS |
Aligos Therapeutics, Inc.
Series B-1 Preferred Stock |
C - Conversion | -198 839 | 0 | -100,00 | ||||
| 2020-10-20 |
|
4 | ALGS |
Aligos Therapeutics, Inc.
Series A Preferred Stock |
C - Conversion | -2 145 991 | 0 | -100,00 | ||||
| 2020-10-20 |
|
4 | ALGS |
Aligos Therapeutics, Inc.
Common Stock |
P - Purchase | 200 000 | 862 444 | 30,19 | 15,00 | 3 000 000 | 12 936 660 | |
| 2020-10-20 |
|
4 | ALGS |
Aligos Therapeutics, Inc.
Common Stock |
C - Conversion | 198 485 | 662 444 | 42,78 | ||||
| 2020-10-20 |
|
4 | ALGS |
Aligos Therapeutics, Inc.
Common Stock |
C - Conversion | 463 959 | 463 959 | |||||
| 2020-10-20 |
|
4 | ALGS |
Aligos Therapeutics, Inc.
Common Stock |
C - Conversion | 85 065 | 2 429 895 | 3,63 | ||||
| 2020-10-20 |
|
4 | ALGS |
Aligos Therapeutics, Inc.
Common Stock |
C - Conversion | 198 839 | 2 344 830 | 9,27 | ||||
| 2020-10-20 |
|
4 | ALGS |
Aligos Therapeutics, Inc.
Common Stock |
C - Conversion | 2 145 991 | 2 145 991 | |||||
| 2020-10-20 |
|
4 | BDTX |
Black Diamond Therapeutics, Inc.
Common Stock |
S - Sale | X | -3 739 | 5 707 536 | -0,07 | 33,43 | -124 998 | 190 808 065 |
| 2020-10-20 |
|
4 | BDTX |
Black Diamond Therapeutics, Inc.
Common Stock |
S - Sale | X | -494 | 995 111 | -0,05 | 33,43 | -16 515 | 33 267 456 |
| 2020-10-20 |
|
4 | BDTX |
Black Diamond Therapeutics, Inc.
Common Stock |
S - Sale | X | -7 697 | 5 711 275 | -0,13 | 33,57 | -258 410 | 191 743 493 |
| 2020-10-20 |
|
4 | BDTX |
Black Diamond Therapeutics, Inc.
Common Stock |
S - Sale | X | -1 016 | 995 605 | -0,10 | 33,57 | -34 110 | 33 425 248 |
| 2020-10-20 |
|
4 | BDTX |
Black Diamond Therapeutics, Inc.
Common Stock |
S - Sale | X | -2 473 | 5 718 972 | -0,04 | 33,03 | -81 694 | 188 922 237 |
| 2020-10-20 |
|
4 | BDTX |
Black Diamond Therapeutics, Inc.
Common Stock |
S - Sale | X | -327 | 996 621 | -0,03 | 33,03 | -10 802 | 32 922 677 |
| 2020-10-15 |
|
4 | BDTX |
Black Diamond Therapeutics, Inc.
Common Stock |
S - Sale | X | -4 859 | 5 721 445 | -0,08 | 33,09 | -160 787 | 189 326 048 |
| 2020-10-15 |
|
4 | BDTX |
Black Diamond Therapeutics, Inc.
Common Stock |
S - Sale | X | -642 | 996 948 | -0,06 | 33,09 | -21 244 | 32 989 607 |
| 2020-10-15 |
|
4 | BDTX |
Black Diamond Therapeutics, Inc.
Common Stock |
S - Sale | X | -10 370 | 5 726 304 | -0,18 | 33,39 | -346 271 | 191 210 453 |
| 2020-10-15 |
|
4 | BDTX |
Black Diamond Therapeutics, Inc.
Common Stock |
S - Sale | X | -1 369 | 997 590 | -0,14 | 33,39 | -45 713 | 33 311 126 |
| 2020-10-13 |
|
4 | BDTX |
Black Diamond Therapeutics, Inc.
Common Stock |
S - Sale | X | -353 | 5 736 674 | -0,01 | 33,11 | -11 687 | 189 926 934 |
| 2020-10-13 |
|
4 | BDTX |
Black Diamond Therapeutics, Inc.
Common Stock |
S - Sale | X | -47 | 998 959 | 0,00 | 33,11 | -1 556 | 33 073 035 |
| 2020-10-13 |
|
4 | BDTX |
Black Diamond Therapeutics, Inc.
Common Stock |
S - Sale | X | -3 357 | 5 737 027 | -0,06 | 33,67 | -113 018 | 193 145 619 |
| 2020-10-13 |
|
4 | BDTX |
Black Diamond Therapeutics, Inc.
Common Stock |
S - Sale | X | -443 | 999 006 | -0,04 | 33,67 | -14 914 | 33 633 035 |
| 2020-10-13 |
|
4 | BDTX |
Black Diamond Therapeutics, Inc.
Common Stock |
S - Sale | X | -8 502 | 5 740 384 | -0,15 | 33,68 | -286 352 | 193 339 577 |
| 2020-10-13 |
|
4 | BDTX |
Black Diamond Therapeutics, Inc.
Common Stock |
S - Sale | X | -7 774 | 5 748 886 | -0,14 | 33,25 | -258 461 | 191 132 638 |
| 2020-10-13 |
|
4 | BDTX |
Black Diamond Therapeutics, Inc.
Common Stock |
S - Sale | X | -1 122 | 999 449 | -0,11 | 33,68 | -37 790 | 33 662 042 |
| 2020-10-13 |
|
4 | BDTX |
Black Diamond Therapeutics, Inc.
Common Stock |
S - Sale | X | -1 027 | 1 000 571 | -0,10 | 33,25 | -34 145 | 33 265 884 |
| 2020-10-08 |
|
4 | BDTX |
Black Diamond Therapeutics, Inc.
Common Stock |
J - Other | -4 131 | 0 | -100,00 | ||||
| 2020-10-08 |
|
4 | BDTX |
Black Diamond Therapeutics, Inc.
Common Stock |
J - Other | 3 098 | 4 131 | 299,90 | ||||
| 2020-10-08 |
|
4 | BDTX |
Black Diamond Therapeutics, Inc.
Common Stock |
J - Other | X | -57 424 | 486 597 | -10,56 | |||
| 2020-10-08 |
|
4 | BDTX |
Black Diamond Therapeutics, Inc.
Common Stock |
J - Other | 1 033 | 1 033 | |||||
| 2020-10-08 |
|
4 | BDTX |
Black Diamond Therapeutics, Inc.
Common Stock |
J - Other | X | -192 576 | 1 631 864 | -10,56 | |||
| 2020-10-08 |
|
4 | BDTX |
Black Diamond Therapeutics, Inc.
Common Stock |
J - Other | -588 | 0 | -100,00 | ||||
| 2020-10-08 |
|
4 | BDTX |
Black Diamond Therapeutics, Inc.
Common Stock |
J - Other | 588 | 588 | |||||
| 2020-10-08 |
|
4 | BDTX |
Black Diamond Therapeutics, Inc.
Common Stock |
J - Other | -593 | 0 | -100,00 | ||||
| 2020-10-08 |
|
4 | BDTX |
Black Diamond Therapeutics, Inc.
Common Stock |
J - Other | 593 | 593 | |||||
| 2020-10-08 |
|
4 | BDTX |
Black Diamond Therapeutics, Inc.
Common Stock |
J - Other | X | -39 608 | 1 001 598 | -3,80 | |||
| 2020-10-08 |
|
4 | BDTX |
Black Diamond Therapeutics, Inc.
Common Stock |
S - Sale | X | -24 590 | 5 756 660 | -0,43 | 33,56 | -825 154 | 193 173 361 |
| 2020-10-08 |
|
4 | BDTX |
Black Diamond Therapeutics, Inc.
Common Stock |
S - Sale | X | -3 246 | 1 041 206 | -0,31 | 33,56 | -108 924 | 34 939 229 |
| 2020-10-08 |
|
4 | BDTX |
Black Diamond Therapeutics, Inc.
Common Stock |
S - Sale | X | -15 980 | 5 781 250 | -0,28 | 33,26 | -531 477 | 192 278 016 |
| 2020-10-08 |
|
4 | BDTX |
Black Diamond Therapeutics, Inc.
Common Stock |
S - Sale | X | -2 110 | 1 044 452 | -0,20 | 33,26 | -70 176 | 34 737 325 |
| 2020-09-21 |
|
4 | BDTX |
Black Diamond Therapeutics, Inc.
Common Stock |
J - Other | -4 131 | 0 | -100,00 | ||||
| 2020-09-21 |
|
4 | BDTX |
Black Diamond Therapeutics, Inc.
Common Stock |
J - Other | 3 098 | 4 131 | 299,90 | ||||
| 2020-09-21 |
|
4 | BDTX |
Black Diamond Therapeutics, Inc.
Common Stock |
J - Other | X | -57 424 | 544 021 | -9,55 | |||
| 2020-09-21 |
|
4 | BDTX |
Black Diamond Therapeutics, Inc.
Common Stock |
J - Other | 1 033 | 1 033 | |||||
| 2020-09-21 |
|
4 | BDTX |
Black Diamond Therapeutics, Inc.
Common Stock |
J - Other | X | -192 576 | 1 824 440 | -9,55 | |||
| 2020-09-21 |
|
4 | BDTX |
Black Diamond Therapeutics, Inc.
Common Stock |
J - Other | -1 177 | 0 | -100,00 | ||||
| 2020-09-21 |
|
4 | BDTX |
Black Diamond Therapeutics, Inc.
Common Stock |
J - Other | 1 177 | 1 177 | |||||
| 2020-09-21 |
|
4 | BDTX |
Black Diamond Therapeutics, Inc.
Common Stock |
J - Other | -1 187 | 0 | -100,00 | ||||
| 2020-09-21 |
|
4 | BDTX |
Black Diamond Therapeutics, Inc.
Common Stock |
J - Other | 1 187 | 1 187 | |||||
| 2020-09-21 |
|
4 | BDTX |
Black Diamond Therapeutics, Inc.
Common Stock |
J - Other | X | -79 216 | 1 046 562 | -7,04 | |||
| 2020-09-21 |
|
4 | BDTX |
Black Diamond Therapeutics, Inc.
Common Stock |
J - Other | -6 901 | 0 | -100,00 | ||||
| 2020-09-21 |
|
4 | BDTX |
Black Diamond Therapeutics, Inc.
Common Stock |
J - Other | 6 901 | 6 901 | |||||
| 2020-09-21 |
|
4 | BDTX |
Black Diamond Therapeutics, Inc.
Common Stock |
J - Other | -8 000 | 0 | -100,00 | ||||
| 2020-09-21 |
|
4 | BDTX |
Black Diamond Therapeutics, Inc.
Common Stock |
J - Other | 8 000 | 8 000 | |||||
| 2020-09-21 |
|
4 | BDTX |
Black Diamond Therapeutics, Inc.
Common Stock |
J - Other | -400 000 | 5 797 230 | -6,45 | ||||
| 2020-08-20 |
|
4 | BDTX |
Black Diamond Therapeutics, Inc.
Common Stock |
J - Other | -5 176 | 0 | -100,00 | ||||
| 2020-08-20 |
|
4 | BDTX |
Black Diamond Therapeutics, Inc.
Common Stock |
J - Other | 5 176 | 5 176 | |||||
| 2020-08-20 |
|
4 | BDTX |
Black Diamond Therapeutics, Inc.
Common Stock |
J - Other | -6 000 | 0 | -100,00 | ||||
| 2020-08-20 |
|
4 | BDTX |
Black Diamond Therapeutics, Inc.
Common Stock |
J - Other | 6 000 | 6 000 | |||||
| 2020-08-20 |
|
4 | BDTX |
Black Diamond Therapeutics, Inc.
Common Stock |
J - Other | -300 000 | 6 197 230 | -4,62 | ||||
| 2020-08-14 |
|
4 | BDTX |
Black Diamond Therapeutics, Inc.
Common Stock |
J - Other | X | -5 176 | 0 | -100,00 | |||
| 2020-08-14 |
|
4 | BDTX |
Black Diamond Therapeutics, Inc.
Common Stock |
J - Other | 5 176 | 5 176 | |||||
| 2020-08-14 |
|
4 | BDTX |
Black Diamond Therapeutics, Inc.
Common Stock |
J - Other | X | -6 000 | 0 | -100,00 | |||
| 2020-08-14 |
|
4 | BDTX |
Black Diamond Therapeutics, Inc.
Common Stock |
J - Other | 6 000 | 6 000 | |||||
| 2020-08-14 |
|
4 | BDTX |
Black Diamond Therapeutics, Inc.
Common Stock |
J - Other | X | -300 000 | 6 497 230 | -4,41 | |||
| 2020-08-12 |
|
4 | BDTX |
Black Diamond Therapeutics, Inc.
Common Stock |
S - Sale | X | -6 692 | 6 797 230 | -0,10 | 33,08 | -221 380 | 224 861 205 |
| 2020-08-12 |
|
4 | BDTX |
Black Diamond Therapeutics, Inc.
Common Stock |
S - Sale | X | -883 | 1 125 778 | -0,08 | 33,08 | -29 211 | 37 242 200 |
| 2020-08-12 |
|
4 | BDTX |
Black Diamond Therapeutics, Inc.
Common Stock |
S - Sale | X | -5 492 | 6 803 922 | -0,08 | 33,04 | -181 446 | 224 789 336 |
| 2020-08-12 |
|
4 | BDTX |
Black Diamond Therapeutics, Inc.
Common Stock |
S - Sale | X | -725 | 1 126 661 | -0,06 | 33,04 | -23 953 | 37 222 851 |
| 2020-07-29 |
|
4 | BDTX |
Black Diamond Therapeutics, Inc.
Common Stock |
J - Other | X | -1 177 | 0 | -100,00 | |||
| 2020-07-29 |
|
4 | BDTX |
Black Diamond Therapeutics, Inc.
Common Stock |
J - Other | 1 177 | 1 177 | |||||
| 2020-07-29 |
|
4 | BDTX |
Black Diamond Therapeutics, Inc.
Common Stock |
J - Other | X | -1 187 | 0 | -100,00 | |||
| 2020-07-29 |
|
4 | BDTX |
Black Diamond Therapeutics, Inc.
Common Stock |
J - Other | 1 187 | 1 187 | |||||
| 2020-07-29 |
|
4 | BDTX |
Black Diamond Therapeutics, Inc.
Common Stock |
J - Other | X | -79 217 | 1 127 386 | -6,57 | |||
| 2020-07-29 |
|
4 | BDTX |
Black Diamond Therapeutics, Inc.
Common Stock |
J - Other | X | -4 131 | 0 | -100,00 | |||
| 2020-07-29 |
|
4 | BDTX |
Black Diamond Therapeutics, Inc.
Common Stock |
J - Other | 3 098 | 4 131 | 299,90 | ||||
| 2020-07-29 |
|
4 | BDTX |
Black Diamond Therapeutics, Inc.
Common Stock |
J - Other | X | -57 424 | 601 445 | -8,72 | |||
| 2020-07-29 |
|
4 | BDTX |
Black Diamond Therapeutics, Inc.
Common Stock |
J - Other | 1 033 | 1 033 | |||||
| 2020-07-29 |
|
4 | BDTX |
Black Diamond Therapeutics, Inc.
Common Stock |
J - Other | X | -192 576 | 2 017 016 | -8,72 | |||
| 2020-07-21 |
|
4 | PAND |
Pandion Therapeutics, Inc.
Simple Agreement for Future Equity |
C - Conversion | -333 333 | 0 | -100,00 | ||||
| 2020-07-21 |
|
4 | PAND |
Pandion Therapeutics, Inc.
Series B Preferred Stock |
C - Conversion | -1 245 330 | 0 | -100,00 | ||||
| 2020-07-21 |
|
4 | PAND |
Pandion Therapeutics, Inc.
Series B Preferred Stock |
C - Conversion | -1 745 458 | 0 | -100,00 | ||||
| 2020-07-21 |
|
4 | PAND |
Pandion Therapeutics, Inc.
Series A Preferred Stock |
C - Conversion | -14 452 795 | 0 | -100,00 | ||||
| 2020-07-21 |
|
4 | PAND |
Pandion Therapeutics, Inc.
Common Stock |
C - Conversion | 577 544 | 577 544 | |||||
| 2020-07-21 |
|
4 | PAND |
Pandion Therapeutics, Inc.
Common Stock |
C - Conversion | 3 176 507 | 3 176 507 | |||||
| 2020-06-25 |
|
4 | RPTX |
Repare Therapeutics Inc.
Class B Preferred Shares |
C - Conversion | -458 282 | 0 | -100,00 | ||||
| 2020-06-25 |
|
4 | RPTX |
Repare Therapeutics Inc.
Class B Preferred Shares |
C - Conversion | -875 568 | 0 | -100,00 | ||||
| 2020-06-25 |
|
4 | RPTX |
Repare Therapeutics Inc.
Class B Preferred Shares |
C - Conversion | -3 350 | 0 | -100,00 | ||||
| 2020-06-25 |
|
4 | RPTX |
Repare Therapeutics Inc.
Class B Preferred Shares |
C - Conversion | -3 708 | 0 | -100,00 | ||||
| 2020-06-25 |
|
4 | RPTX |
Repare Therapeutics Inc.
Class B Preferred Shares |
C - Conversion | -8 475 | 0 | -100,00 | ||||
| 2020-06-25 |
|
4 | RPTX |
Repare Therapeutics Inc.
Class B Preferred Shares |
C - Conversion | -111 361 | 0 | -100,00 | ||||
| 2020-06-25 |
|
4 | RPTX |
Repare Therapeutics Inc.
Class A Preferred Shares |
C - Conversion | -2 443 883 | 0 | -100,00 | ||||
| 2020-06-25 |
|
4 | RPTX |
Repare Therapeutics Inc.
Class A Preferred Shares |
C - Conversion | -61 791 | 0 | -100,00 | ||||
| 2020-06-25 |
|
4 | RPTX |
Repare Therapeutics Inc.
Class A Preferred Shares |
C - Conversion | -68 398 | 0 | -100,00 | ||||
| 2020-06-25 |
|
4 | RPTX |
Repare Therapeutics Inc.
Class A Preferred Shares |
C - Conversion | -156 335 | 0 | -100,00 | ||||
| 2020-06-25 |
|
4 | RPTX |
Repare Therapeutics Inc.
Class A Preferred Shares |
C - Conversion | -2 054 198 | 0 | -100,00 | ||||
| 2020-06-25 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
P - Purchase | 100 000 | 3 419 451 | 3,01 | 20,00 | 2 000 000 | 68 389 020 | |
| 2020-06-25 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
P - Purchase | 150 000 | 608 282 | 32,73 | 20,00 | 3 000 000 | 12 165 640 | |
| 2020-06-25 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
C - Conversion | 458 282 | 458 282 | |||||
| 2020-06-25 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
C - Conversion | 875 568 | 3 319 451 | 35,83 | ||||
| 2020-06-25 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
C - Conversion | 3 350 | 84 737 | 4,12 | ||||
| 2020-06-25 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
C - Conversion | 3 708 | 93 798 | 4,12 | ||||
| 2020-06-25 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
C - Conversion | 8 475 | 214 390 | 4,12 | ||||
| 2020-06-25 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
C - Conversion | 111 361 | 2 817 021 | 4,12 | ||||
| 2020-06-25 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
C - Conversion | 2 443 883 | 2 443 883 | |||||
| 2020-06-25 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
C - Conversion | 61 791 | 81 387 | 315,32 | ||||
| 2020-06-25 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
C - Conversion | 68 398 | 90 090 | 315,31 | ||||
| 2020-06-25 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
C - Conversion | 156 335 | 205 915 | 315,32 | ||||
| 2020-06-25 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
C - Conversion | 2 054 198 | 2 705 660 | 315,32 | ||||
| 2020-06-18 | 3 | RPTX |
Repare Therapeutics Inc.
Common Shares |
1 393 792 | ||||||||
| 2020-06-18 | 3 | RPTX |
Repare Therapeutics Inc.
Common Shares |
791 910 | ||||||||
| 2020-06-18 | 3 | RPTX |
Repare Therapeutics Inc.
Common Shares |
764 022 | ||||||||
| 2020-06-18 | 3 | RPTX |
Repare Therapeutics Inc.
Common Shares |
761 926 | ||||||||
| 2020-06-18 | 3 | RPTX |
Repare Therapeutics Inc.
Common Shares |
1 393 792 | ||||||||
| 2020-06-18 | 3 | RPTX |
Repare Therapeutics Inc.
Common Shares |
791 910 | ||||||||
| 2020-06-18 | 3 | RPTX |
Repare Therapeutics Inc.
Common Shares |
764 022 | ||||||||
| 2020-06-18 | 3 | RPTX |
Repare Therapeutics Inc.
Common Shares |
761 926 | ||||||||
| 2020-06-18 | 3 | RPTX |
Repare Therapeutics Inc.
Common Shares |
1 393 792 | ||||||||
| 2020-06-18 | 3 | RPTX |
Repare Therapeutics Inc.
Common Shares |
791 910 | ||||||||
| 2020-06-18 | 3 | RPTX |
Repare Therapeutics Inc.
Common Shares |
764 022 | ||||||||
| 2020-06-18 | 3 | RPTX |
Repare Therapeutics Inc.
Common Shares |
761 926 | ||||||||
| 2020-06-18 | 3 | RPTX |
Repare Therapeutics Inc.
Common Shares |
1 393 792 | ||||||||
| 2020-06-18 | 3 | RPTX |
Repare Therapeutics Inc.
Common Shares |
791 910 | ||||||||
| 2020-06-18 | 3 | RPTX |
Repare Therapeutics Inc.
Common Shares |
764 022 | ||||||||
| 2020-06-18 | 3 | RPTX |
Repare Therapeutics Inc.
Common Shares |
761 926 | ||||||||
| 2020-06-18 | 3 | RPTX |
Repare Therapeutics Inc.
Common Shares |
1 393 792 | ||||||||
| 2020-06-18 | 3 | RPTX |
Repare Therapeutics Inc.
Common Shares |
791 910 | ||||||||
| 2020-06-18 | 3 | RPTX |
Repare Therapeutics Inc.
Common Shares |
764 022 | ||||||||
| 2020-06-18 | 3 | RPTX |
Repare Therapeutics Inc.
Common Shares |
761 926 | ||||||||
| 2020-05-20 |
|
4 | APRE |
Aprea Therapeutics, Inc.
Common Stock |
J - Other | -1 734 | 0 | -100,00 | ||||
| 2020-05-20 |
|
4 | APRE |
Aprea Therapeutics, Inc.
Common Stock |
J - Other | 1 734 | 1 734 | |||||
| 2020-05-20 |
|
4 | APRE |
Aprea Therapeutics, Inc.
Common Stock |
J - Other | -1 750 | 0 | -100,00 | ||||
| 2020-05-20 |
|
4 | APRE |
Aprea Therapeutics, Inc.
Common Stock |
J - Other | 1 750 | 1 750 | |||||
| 2020-05-20 |
|
4 | APRE |
Aprea Therapeutics, Inc.
Common Stock |
J - Other | -116 664 | 216 669 | -35,00 | ||||
| 2020-03-03 |
|
4 | PASG |
Passage BIO, Inc.
Series B Preferred Stock |
C - Conversion | -708 352 | 0 | -100,00 | ||||
| 2020-03-03 |
|
4 | PASG |
Passage BIO, Inc.
Series A-2 Preferred Stock |
C - Conversion | -1 049 175 | 0 | -100,00 | ||||
| 2020-03-03 |
|
4 | PASG |
Passage BIO, Inc.
Series A-1 Preferred Stock |
C - Conversion | -2 977 242 | 0 | -100,00 | ||||
| 2020-03-03 |
|
4 | PASG |
Passage BIO, Inc.
Common Stock |
P - Purchase | 225 000 | 933 352 | 31,76 | 18,00 | 4 050 000 | 16 800 336 | |
| 2020-03-03 |
|
4 | PASG |
Passage BIO, Inc.
Common Stock |
C - Conversion | 708 352 | 708 352 | |||||
| 2020-03-03 |
|
4 | PASG |
Passage BIO, Inc.
Common Stock |
C - Conversion | 1 049 175 | 4 026 417 | 35,24 | ||||
| 2020-03-03 |
|
4 | PASG |
Passage BIO, Inc.
Common Stock |
C - Conversion | 2 977 242 | 2 977 242 | |||||
| 2020-02-05 |
|
4 | BDTX |
Black Diamond Therapeutics, Inc.
Series C Preferred Stock |
C - Conversion | -2 444 382 | 0 | -100,00 | ||||
| 2020-02-05 |
|
4 | BDTX |
Black Diamond Therapeutics, Inc.
Series C Preferred Stock |
C - Conversion | -1 055 960 | 0 | -100,00 | ||||
| 2020-02-05 |
|
4 | BDTX |
Black Diamond Therapeutics, Inc.
Series C Preferred Stock |
C - Conversion | -314 873 | 0 | -100,00 | ||||
| 2020-02-05 |
|
4 | BDTX |
Black Diamond Therapeutics, Inc.
Series C Preferred Stock |
C - Conversion | -1 370 833 | 0 | -100,00 | ||||
| 2020-02-05 |
|
4 | BDTX |
Black Diamond Therapeutics, Inc.
Series B Preferred Stock |
C - Conversion | -1 517 940 | 0 | -100,00 | ||||
| 2020-02-05 |
|
4 | BDTX |
Black Diamond Therapeutics, Inc.
Series B Preferred Stock |
C - Conversion | -452 630 | 0 | -100,00 | ||||
| 2020-02-05 |
|
4 | BDTX |
Black Diamond Therapeutics, Inc.
Series B Preferred Stock |
C - Conversion | -1 970 572 | 0 | -100,00 | ||||
| 2020-02-05 |
|
4 | BDTX |
Black Diamond Therapeutics, Inc.
Series A Preferred Stock |
C - Conversion | -3 851 526 | 0 | -100,00 | ||||
| 2020-02-05 |
|
4 | BDTX |
Black Diamond Therapeutics, Inc.
Series A Preferred Stock |
C - Conversion | -1 148 474 | 0 | -100,00 | ||||
| 2020-02-05 |
|
4 | BDTX |
Black Diamond Therapeutics, Inc.
Series A Preferred Stock |
C - Conversion | -15 000 000 | 0 | -100,00 | ||||
| 2020-02-05 |
|
4 | BDTX |
Black Diamond Therapeutics, Inc.
Common Stock |
P - Purchase | 396 081 | 1 206 603 | 48,87 | 19,00 | 7 525 539 | 22 925 457 | |
| 2020-02-05 |
|
4 | BDTX |
Black Diamond Therapeutics, Inc.
Common Stock |
P - Purchase | 396 082 | 6 809 414 | 6,18 | 19,00 | 7 525 558 | 129 378 866 | |
| 2020-02-05 |
|
4 | BDTX |
Black Diamond Therapeutics, Inc.
Common Stock |
P - Purchase | 23 560 | 658 869 | 3,71 | 19,00 | 447 640 | 12 518 511 | |
| 2020-02-05 |
|
4 | BDTX |
Black Diamond Therapeutics, Inc.
Common Stock |
P - Purchase | 79 013 | 2 209 592 | 3,71 | 19,00 | 1 501 247 | 41 982 248 | |
| 2020-02-05 |
|
4 | BDTX |
Black Diamond Therapeutics, Inc.
Common Stock |
C - Conversion | 810 522 | 810 522 | |||||
| 2020-02-05 |
|
4 | BDTX |
Black Diamond Therapeutics, Inc.
Common Stock |
C - Conversion | 350 141 | 2 130 579 | 19,67 | ||||
| 2020-02-05 |
|
4 | BDTX |
Black Diamond Therapeutics, Inc.
Common Stock |
C - Conversion | 104 407 | 635 309 | 19,67 | ||||
| 2020-02-05 |
|
4 | BDTX |
Black Diamond Therapeutics, Inc.
Common Stock |
C - Conversion | 454 548 | 6 413 332 | 7,63 | ||||
| 2020-02-05 |
|
4 | BDTX |
Black Diamond Therapeutics, Inc.
Common Stock |
C - Conversion | 503 327 | 1 780 438 | 39,41 | ||||
| 2020-02-05 |
|
4 | BDTX |
Black Diamond Therapeutics, Inc.
Common Stock |
C - Conversion | 150 085 | 530 902 | 39,41 | ||||
| 2020-02-05 |
|
4 | BDTX |
Black Diamond Therapeutics, Inc.
Common Stock |
C - Conversion | 653 412 | 5 958 784 | 12,32 | ||||
| 2020-02-05 |
|
4 | BDTX |
Black Diamond Therapeutics, Inc.
Common Stock |
C - Conversion | 1 277 111 | 1 277 111 | |||||
| 2020-02-05 |
|
4 | BDTX |
Black Diamond Therapeutics, Inc.
Common Stock |
C - Conversion | 380 817 | 380 817 | |||||
| 2020-02-05 |
|
4 | BDTX |
Black Diamond Therapeutics, Inc.
Common Stock |
C - Conversion | 4 973 787 | 5 305 372 | 1 500,00 | ||||
| 2020-01-29 | 3 | BDTX |
Black Diamond Therapeutics, Inc.
Common Stock |
663 170 | ||||||||
| 2020-01-29 | 3 | BDTX |
Black Diamond Therapeutics, Inc.
Common Stock |
663 170 | ||||||||
| 2020-01-29 | 3 | BDTX |
Black Diamond Therapeutics, Inc.
Common Stock |
663 170 | ||||||||
| 2020-01-29 | 3 | BDTX |
Black Diamond Therapeutics, Inc.
Common Stock |
663 170 | ||||||||
| 2020-01-29 | 3 | BDTX |
Black Diamond Therapeutics, Inc.
Common Stock |
663 170 | ||||||||
| 2020-01-29 | 3 | BDTX |
Black Diamond Therapeutics, Inc.
Common Stock |
663 170 | ||||||||
| 2019-11-04 |
|
4 | OYST |
Oyster Point Pharma, Inc.
Series B Convertible Preferred Stock |
C - Conversion | -566 158 | 0 | -100,00 | ||||
| 2019-11-04 |
|
4 | OYST |
Oyster Point Pharma, Inc.
Series B Convertible Preferred Stock |
C - Conversion | -495 388 | 0 | -100,00 | ||||
| 2019-11-04 |
|
4 | OYST |
Oyster Point Pharma, Inc.
Series A Convertible Preferred Stock |
C - Conversion | -1 941 500 | 0 | -100,00 | ||||
| 2019-11-04 |
|
4 | OYST |
Oyster Point Pharma, Inc.
Series A Convertible Preferred Stock |
C - Conversion | -1 654 359 | 0 | -100,00 | ||||
| 2019-11-04 |
|
4 | OYST |
Oyster Point Pharma, Inc.
Series A Convertible Preferred Stock |
C - Conversion | -10 420 | 0 | -100,00 | ||||
| 2019-11-04 |
|
4 | OYST |
Oyster Point Pharma, Inc.
Common Stock, par value $0.001 per share |
P - Purchase | 437 500 | 1 003 658 | 77,28 | 16,00 | 7 000 000 | 16 058 528 | |
| 2019-11-04 |
|
4 | OYST |
Oyster Point Pharma, Inc.
Common Stock, par value $0.001 per share |
C - Conversion | 566 158 | 566 158 | |||||
| 2019-11-04 |
|
4 | OYST |
Oyster Point Pharma, Inc.
Common Stock, par value $0.001 per share |
P - Purchase | 125 000 | 2 561 888 | 5,13 | 16,00 | 2 000 000 | 40 990 208 | |
| 2019-11-04 |
|
4 | OYST |
Oyster Point Pharma, Inc.
Common Stock, par value $0.001 per share |
C - Conversion | 495 388 | 2 436 888 | 25,52 | ||||
| 2019-11-04 |
|
4 | OYST |
Oyster Point Pharma, Inc.
Common Stock, par value $0.001 per share |
C - Conversion | 1 941 500 | 1 941 500 | |||||
| 2019-11-04 |
|
4 | OYST |
Oyster Point Pharma, Inc.
Common Stock, par value $0.001 per share |
P - Purchase | 27 500 | 2 002 298 | 1,39 | 16,00 | 440 000 | 32 036 768 | |
| 2019-11-04 |
|
4 | OYST |
Oyster Point Pharma, Inc.
Common Stock, par value $0.001 per share |
C - Conversion | 1 654 359 | 1 974 798 | 516,28 | ||||
| 2019-11-04 |
|
4 | OYST |
Oyster Point Pharma, Inc.
Common Stock, par value $0.001 per share |
C - Conversion | 10 420 | 12 438 | 516,35 | ||||
| 2019-10-30 | 3 | OYST |
Oyster Point Pharma, Inc.
Common Stock, par value $0.001 per share |
324 475 | ||||||||
| 2019-10-30 | 3 | OYST |
Oyster Point Pharma, Inc.
Common Stock, par value $0.001 per share |
642 896 | ||||||||
| 2019-10-30 | 3 | OYST |
Oyster Point Pharma, Inc.
Common Stock, par value $0.001 per share |
324 475 | ||||||||
| 2019-10-30 | 3 | OYST |
Oyster Point Pharma, Inc.
Common Stock, par value $0.001 per share |
642 896 | ||||||||
| 2019-10-30 | 3 | OYST |
Oyster Point Pharma, Inc.
Common Stock, par value $0.001 per share |
324 475 | ||||||||
| 2019-10-30 | 3 | OYST |
Oyster Point Pharma, Inc.
Common Stock, par value $0.001 per share |
642 896 | ||||||||
| 2019-10-30 | 3 | OYST |
Oyster Point Pharma, Inc.
Common Stock, par value $0.001 per share |
324 475 | ||||||||
| 2019-10-30 | 3 | OYST |
Oyster Point Pharma, Inc.
Common Stock, par value $0.001 per share |
642 896 | ||||||||
| 2019-10-30 | 3 | OYST |
Oyster Point Pharma, Inc.
Common Stock, par value $0.001 per share |
324 475 | ||||||||
| 2019-10-30 | 3 | OYST |
Oyster Point Pharma, Inc.
Common Stock, par value $0.001 per share |
642 896 | ||||||||
| 2019-10-30 | 3 | OYST |
Oyster Point Pharma, Inc.
Common Stock, par value $0.001 per share |
324 475 | ||||||||
| 2019-10-30 | 3 | OYST |
Oyster Point Pharma, Inc.
Common Stock, par value $0.001 per share |
642 896 | ||||||||
| 2019-10-30 | 3 | OYST |
Oyster Point Pharma, Inc.
Common Stock, par value $0.001 per share |
324 475 | ||||||||
| 2019-10-30 | 3 | OYST |
Oyster Point Pharma, Inc.
Common Stock, par value $0.001 per share |
642 896 | ||||||||
| 2019-10-30 | 3 | OYST |
Oyster Point Pharma, Inc.
Common Stock, par value $0.001 per share |
324 475 | ||||||||
| 2019-10-30 | 3 | OYST |
Oyster Point Pharma, Inc.
Common Stock, par value $0.001 per share |
642 896 | ||||||||
| 2019-10-30 | 3 | OYST |
Oyster Point Pharma, Inc.
Common Stock, par value $0.001 per share |
324 475 | ||||||||
| 2019-10-30 | 3 | OYST |
Oyster Point Pharma, Inc.
Common Stock, par value $0.001 per share |
642 896 | ||||||||
| 2019-10-30 | 3 | OYST |
Oyster Point Pharma, Inc.
Common Stock, par value $0.001 per share |
324 475 | ||||||||
| 2019-10-30 | 3 | OYST |
Oyster Point Pharma, Inc.
Common Stock, par value $0.001 per share |
642 896 | ||||||||
| 2019-10-30 | 3 | OYST |
Oyster Point Pharma, Inc.
Common Stock, par value $0.001 per share |
324 475 | ||||||||
| 2019-10-30 | 3 | OYST |
Oyster Point Pharma, Inc.
Common Stock, par value $0.001 per share |
642 896 | ||||||||
| 2019-10-07 |
|
4 | APRE |
Aprea Therapeutics, Inc.
Series C Convertible Preferred Stock |
C - Conversion | -512 995 | 0 | -100,00 | ||||
| 2019-10-07 |
|
4 | APRE |
Aprea Therapeutics, Inc.
Series B Convertible Preferred Stock |
C - Conversion | -1 993 658 | 0 | -100,00 | ||||
| 2019-10-07 |
|
4 | APRE |
Aprea Therapeutics, Inc.
Common Stock |
P - Purchase | 333 333 | 333 333 | 15,00 | 4 999 995 | 4 999 995 | ||
| 2019-10-07 |
|
4 | APRE |
Aprea Therapeutics, Inc.
Common Stock |
C - Conversion | 512 995 | 2 519 323 | 25,57 | ||||
| 2019-10-07 |
|
4 | APRE |
Aprea Therapeutics, Inc.
Common Stock |
C - Conversion | 1 993 658 | 2 006 328 | 15 735,26 |
